Published on 06/12/2025
Wider use of new tools against malaria, including dual-ingredient nets and World Health Organization (WHO) -recommended vaccines helped to prevent an estimated 170 million cases and 1 million deaths in 2024, according to WHO’s annual World malaria report.
WHO-recommended tools are increasingly being integrated into broader health systems. Since WHO approved the world’s first malaria vaccines in 2021, 24 countries have introduced the vaccines into their routine immunization programmes. Seasonal malaria chemoprevention has also been expanded and is now being implemented in 20 countries, reaching 54 million children in 2024, an increase from about 0.2 million in 2012.
DOWNLOAD REPORT
World malaria report 2025
Antimalarial drug resistance challenging progress
Each year, WHO’s World malaria report provides a comprehensive and up-to-date assessment of trends in malaria control and elimination across the globe. The 2024 edition reviews investments in malaria programmes and research and assesses progress across all major intervention areas – prevention, diagnosis, treatment, elimination and surveillance – in 80 malaria-endemic countries.
This year’s report spotlights the growing threat of antimalarial drug resistance. Partial resistance to artemisinin derivatives – the backbone of malaria treatments after failures of chloroquine and sulfadoxine-pyrimethamine – has now been confirmed or suspected in at least 8 countries in Africa, and there are potential signs of declining efficacy of some of the drugs that are combined with artemisinin.
Progress is also being made in eliminating malaria. To date, a total of 47 countries and 1 territory have been certified malaria-free by WHO – Cabo Verde and Egypt were certified malaria-free in 2024, and Georgia, Suriname, and Timor-Leste joined them in 2025. Despite this significant progress, there were an estimated 282 million malaria cases and 610 000 deaths in 2024 – roughly 9 million more cases than the previous year.
An estimated 95% of these deaths were in the WHO African Region, with most occurring among children under 5. The report shows that antimalarial drug resistance is growing and stands in the way of achieving malaria elimination.
“New tools for prevention of malaria are giving us new hope, but we still face significant challenges,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Increasing numbers of cases and deaths, the growing threat of drug resistance and the impact of funding cuts all threaten to roll back the progress we have made over the past two decades. However, none of these challenges is insurmountable. With the leadership of the most-affected countries and targeted investment, the vision of a malaria-free world remains achievable.”
The World malaria report spotlights evidence on partial resistance to artemisinin derivatives, which became the backbone of malaria treatments after failures of chloroquine and sulfadoxine-pyrimethamine. Antimalarial drug resistance has now been confirmed or suspected in at least 8 countries in Africa, and there are potential signs of declining efficacy of the drugs that are combined with artemisinin.
Progress in reducing the malaria deaths – a key target of the Global technical strategy for malaria 2016-2030 – remains far off track. In 2024, there were 610 000 deaths. This corresponds to 13.8 malaria deaths per 100 000 population, more than 3 times the global target of 4.5 deaths per 100 000.
Complex challenges to progress
This year’s report underscores a growing array of risks to malaria elimination efforts in addition to the threat of antimalarial drug resistance.
Malaria parasites with pfhrp2 gene deletions remain prevalent, undermining the reliability of rapid diagnostic tests, while confirmed pyrethroid resistance in 48 countries is reducing the effectiveness of insecticide-treated nets. At the same time, Anopheles stephensi mosquitoes – resistant to many commonly used insecticides – have now invaded 9 African countries, posing a serious challenge to urban malaria control efforts.
Beyond biological threats, extreme weather events are also contributing to increased outbreaks of malaria. Changes in temperature and rainfall are altering habitats for mosquitoes and thus transmission patterns.
Conflict and instability in affected regions are also leading to widespread disruptions of health services, limiting access to care and delaying timely diagnosis and treatment.
The challenge is further exacerbated by the plateauing of global funding over the last decade limiting the reach of life-saving interventions. In 2024, US$3.9 billion was invested in the malaria response, yet it reached less than half of the 2025 funding target of US$9.3 billion set by the Global technical strategy.
Recent reductions in Official Development Assistance (ODA) have severely disrupted health systems, weakening routine surveillance and forcing the cancellation or postponement of most planned malaria surveys. These cuts have also heightened the risk of stock-outs and delays in malaria interventions campaigns, undermining programme impact.
Country led, partner enabled response
“The World Malaria Report is clear: drug resistance is advancing. Our response must be equally clear – new medicines with new mechanisms of action,” said Dr Martin Fitchet CEO of Medicines for Malaria Venture. “The development of the first non-artemisinin combination therapy, Ganaplacide–Lumefantrine, is proof that this is possible, and it represents the beginning of a new chapter in malaria resilience. Together with a global partnership of expertise, commitment and funding, we can stay ahead of resistance and deliver new medicines to ensure malaria is no longer a threat.”
Political commitments need to be translated into resources and actions with sustainable and equitable impact. WHO urges malaria-endemic countries to maintain their political commitments to ending malaria deaths as outlined in the Yaoundé Declaration. Unity and action under the Big Push initiative will help global malaria community mitigate current and future threats to achieve a malaria-free future.
